Northwest Biotherapeutics (NWBO) Free Cash Flow Growth (3y) (2013 - 2026)
Northwest Biotherapeutics (NWBO) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Northwest Biotherapeutics | 272.75 Mn | 270.97 Mn | - | -0.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.17% |
| Dec 31, 2025 | -12.49% |
| Sep 30, 2025 | 4.91% |
| Jun 30, 2025 | 22.89% |
| Mar 31, 2025 | 9.95% |
| Dec 31, 2024 | -16.54% |
| Sep 30, 2024 | 4.66% |
| Jun 30, 2024 | -26.30% |
| Mar 31, 2024 | 2.19% |
| Dec 31, 2023 | -9.42% |
| Sep 30, 2023 | -11.83% |
| Jun 30, 2023 | -19.03% |
| Mar 31, 2023 | -18.26% |
| Dec 31, 2022 | -21.80% |
| Sep 30, 2022 | -36.31% |
| Jun 30, 2022 | -15.48% |
| Mar 31, 2022 | -10.13% |
| Dec 31, 2021 | 3.35% |
| Sep 30, 2021 | -33.78% |
| Jun 30, 2021 | 10.48% |